Renal Cell CarcinomaNCT06055660
Moesin Expression in Clear Cell Renal Cell Carcinoma
An observational study of Renal Cell Carcinoma, run by Sohag University.
Trial summary
Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Renal Cell Carcinoma
- What is being tested?
- Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2017to 31 Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: The present work will be performed on archived formalin-fixed, paraffin-embedded renal cell carcinoma tissue blocks that were belonged to 55 patients who were admitted to Sohag University Hospital because of loin/ back pain, from January 1st,2017 to December 31st, 2021. Radiological evaluation revealed renal neoplasms and patients underwent radical nephrectomies.
Who may be able to join
- All cases of ccRCC.
- Tissue blocks with material adequate for immunohistochemical evaluation.
- All cases with accessible clinical data.
Who cannot join
- Cases of renal neoplasms other than ccRCC.
- Patients who received preoperative chemotherapy or radiotherapy.
- Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.
- Cases with insufficient/destructed material.
- Patients with inadequate clinical data.
About this study
Official title: Expression and Distribution of Membrane-Organizing Extension Spike Protein (Moesin/ MSN) is Associated With Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma.
Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.
- Conditions
- Renal Cell Carcinoma
- Being tested
- Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
- Keywords
- Renal Cell Carcinoma, Moesin, Epithelial-Mesenchymal Transition
- Medical subject headings
- Carcinoma, Renal Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Immunohistochemical detection of Moesin in Clear cell Renal Cell CarcinomaGenetic
Formalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody.
What is being measured
The primary outcome is the main question the study is designed to answer.
Detection of Moesin in renal cell carcinoma
different levels of moesin expression will be correlated with some tumor characteristics as patients' ages, sexes, tumor site, tumor grades, stages and nodal statuses.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2023
- Study start1 Jan 2017
- Primary completion31 Oct 2021
- Study completion31 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal Cell CarcinomaStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maisa Hashem Mohammed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06055660
- Sponsor's protocol ID
- Soh-Med-23-09-5PD
- Status last verified
- Sep 2023
- First submitted
- 20 Sep 2023
- Last updated
- 28 Sep 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expression and Distribution of Membrane-Organizing Extension Spike Protein (Moesin/ MSN) is Associated With Epithelial-Mesenchymal Transition in Clear Cell Renal Cell Carcinoma.
- ClinicalTrials.gov ID
- NCT06055660
- Acronym / sponsor ID
- Soh-Med-23-09-5PD
- Conditions
- Renal Cell Carcinoma
- Keywords
- Renal Cell Carcinoma, Moesin, Epithelial-Mesenchymal Transition
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Jan 2017 (actual)
- Primary completion
- 31 Oct 2021 (actual)
- Study completion
- 31 Dec 2021 (actual)
- First posted
- 28 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- The present work will be performed on archived formalin-fixed, paraffin-embedded renal cell carcinoma tissue blocks that were belonged to 55 patients who were admitted to Sohag University Hospital because of loin/ back pain, from January 1st,2017 to December 31st, 2021. Radiological evaluation revealed renal neoplasms and patients underwent radical nephrectomies.
Key inclusion criteria (3 listed)
- All cases of ccRCC.
- Tissue blocks with material adequate for immunohistochemical evaluation.
- All cases with accessible clinical data.
Key exclusion criteria (5 listed)
- Cases of renal neoplasms other than ccRCC.
- Patients who received preoperative chemotherapy or radiotherapy.
- Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.
- Cases with insufficient/destructed material.
- Patients with inadequate clinical data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Immunohistochemical detection of Moesin in Clear cell Renal Cell CarcinomaFormalin-fixed paraffin-embedded renal cell carcinoma tissue blocks will be sectioned and immunohistochemically stained by anti moesin antibody. | Genetic | – |
Primary outcome
Detection of Moesin in renal cell carcinoma
Time frame: 6 months
different levels of moesin expression will be correlated with some tumor characteristics as patients' ages, sexes, tumor site, tumor grades, stages and nodal statuses.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Renal Cell Carcinoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Not yet recruitingPhase 2
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Not yet recruitingPhase 2
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
Localized Clear Cell Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Renal Cell Carcinoma, run by Sohag University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Detection of Moesin in renal cell carcinoma (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.